Finance

Lists
Outlook: 70.0% bullish·10.0% bearish
Go to analysis
ELV:NYSE
Elevance Health Inc
$400.94
-0.83%
(-3.37) 1D
$400.95
+0.00% (+0.010)
Pre-market
Closed: Oct 8, 4:00:02 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ELV...
Open
$403.83
High
$407.37
Low
$397.12
Mkt. cap
87.68B
Avg. vol.
1.14M
Volume
57.00
52-wk high
$436.24
52-wk low
$274.84
Beta
0.70
Shares outstanding
216.87M
No. of employees
97K
Open
$403.83
High
$407.37
Low
$397.12
Mkt. cap
87.68B
Avg. vol.
1.14M
Volume
57.00
52-wk high
$436.24
52-wk low
$274.84
Beta
0.70
Shares outstanding
216.87M
No. of employees
97K
News stories
From web sources and news partners
Profile
Elevance Health, Inc. is an American health insurance company. Prior to June 2022, Elevance Health was named Anthem, Inc. The company is the world's seventh largest healthcare company based on revenue. Its services include medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans through affiliated companies such as Anthem Blue Cross and Blue Shield, Anthem Blue Cross in California, Wellpoint, and Carelon. It is the largest for-profit managed health care company in the Blue Cross Blue Shield Association. As of 2022, the company had 46.8 million members within its affiliated companies' health plans. Based on its 2021 revenues, the company ranked 20th on the 2022 Fortune 500. In 2023, the company's seat in Forbes Global 2000 rankings was 78. Carelon Global Solutions, Elevance Health's Business Process Outsourcing /Shared Services subsidiary, serves the group's offshore and customer service management. It operates sites in India, Puerto Rico, Philippines, and the United States. Wikipedia
About Elevance Health Inc
CEOGail Koziara Boudreaux
Employees96.6K
Founded1944
HeadquartersIndianapolis, Indiana, United States
SectorHealth care provider
Websiteelevancehealth.com
Analyst ratings
Based on 17 analysts giving stock ratings to ELV in the past 3 months
Buy
Buy
10
Hold
7
Sell
0
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for ELV in the last 3 months.
Highest
Current $400.94
$488.00 (+21.71%)
Average
$446.40 (+11.34%)
Lowest
$393.00 (-1.98%)
Analyst
Recommendation
Action
Price target
Projected
Date
Andrew Mok CFA
Barclays
Buy
Maintained
$469.00
+17%
10/07/2026
Ben Hendrix
RBC Capital
Hold
Maintained
$424.00
+5.8%
10/07/2026
Lance Wilkes
Bernstein
Buy
Maintained
$488.00
+21.7%
10/05/2026
A.J. Rice
UBS
Buy
Maintained
$460.00
+14.7%
09/18/2026
Stephen Baxter
Wells Fargo
Buy
Maintained
$473.00
+18%
09/15/2026
Kevin Fischbeck
Bank of America Securities
Buy
Maintained
$480.00
+19.7%
09/11/2026
David Toung
Argus Research
Hold
Maintained
-
-
08/20/2026
Whit Mayo
Leerink Partners
Hold
Reiterated
$395.00
-1.5%
07/17/2026
Ryan Langston
TD Cowen
Buy
Reiterated
$465.00
+16%
07/17/2026
David Windley
Jefferies
Buy
Maintained
$450.00
+12.2%
07/16/2026
Scott Fidel
Goldman Sachs
Hold
Maintained
$395.00
-1.5%
07/15/2026
Erin Wright
Morgan Stanley
Hold
Reiterated
$404.00
+0.8%
07/17/2026
Jason Cassorla
Guggenheim
Buy
Maintained
$455.00
+13.5%
07/15/2026
Michael Ha
Robert W. Baird
Hold
Maintained
$393.00
-2%
07/16/2026
Amit Daryanani
Evercore ISI
Hold
Maintained
-
-
07/15/2026
David S Macdonald
Truist Financial
Buy
Reiterated
$475.00
+18.5%
07/16/2026
Ann Hynes
Mizuho Securities
Buy
Maintained
$470.00
+17.2%
07/13/2026
Sarah James
Cantor Fitzgerald
Buy
Maintained
$450.00
+12.2%
07/07/2026
Lisa Gill
J.P. Morgan
Buy
Maintained
$476.00
+18.7%
06/08/2026
George Hill
Deutsche Bank
Buy
Upgraded
$498.00
+24.2%
05/20/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Upgraded
$360.00
-10.2%
05/19/2026
Next call in 12 days
Wed, Oct 21, 2:30 PM
Fiscal period
Q3 2026
- / $4.69
Revenue / Est. (USD)
- / 49.16B
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
50.71B
49.75B
50.18B
50.47B
Cost of goods sold
38.14B
38.06B
35.62B
37.02B
Cost of revenue
38.14B
38.06B
35.62B
37.02B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.65B
10.75B
11.79B
11.04B
Operating expense
10.81B
10.92B
11.90B
11.15B
Total operating expenses
48.95B
48.98B
47.52B
48.17B
Operating income
1.76B
766.00M
2.66B
2.30B
Other non operating income
-
-
-
-
EBT including unusual items
1.41B
215.00M
2.30B
1.94B
EBT excluding unusual items
1.41B
399.00M
2.30B
1.94B
Income tax expense
219.00M
-331.00M
544.00M
483.00M
Effective tax rate
15.58%
-153.95%
23.61%
24.94%
Other operating expenses
-
-
-
-
Net income
1.19B
547.00M
1.76B
1.46B
Net profit margin
2.34%
1.10%
3.52%
2.90%
Earnings per share
6.03
3.33
12.58
7.45
Interest and investment income
-
-
-
-
Interest expense
-351.00M
-367.00M
-357.00M
-364.00M
Net interest expenses
-351.00M
-367.00M
-357.00M
-364.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
2.14B
1.17B
3.02B
2.67B
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps